Allosteros Therapeutics, Inc. is a drug discovery company structured around development of novel, potent, and selective small molecule of a critical signaling pathway that promotes heart disease enabling Users to get candidate selection and planned stepwise development of inhibitors for several cardiovascular indications. Inhibitors of a Ca2+-dependent protein kinase called CaMKII show positive preclinical proof of concept in atrial fibrillation and ventricular arrhythmia by normalizing Ca2+ homeostasis that also underlies heart failure.
